Has Novogen Limited really made a blockbuster breakthrough?

Biotech business Novogen Limited (ASX:NRT) says it has made a potentially significant breakthrough in the treatment of melanoma.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dual-listed biotech business Novogen Limited (ASX: NRT) (NASDAQ: NVGN) yesterday announced a potentially important breakthrough in its quest to grow into a global pharmaceutical force via its best-in-class proprietary drug technology.

The company says pre-clinical trials have shown that its lead candidate product, TRXE-009 or Trilexium, is highly active in the treatment of melanomas. The drug was originally developed for the treatment of brain cancers.

The company also says the drug could potentially be used for the treatment of secondary brain cancers due to melanoma, for which there are currently no effective therapies.

Novogen also claims it has found evidence for the first time of an hypothesized link between brain cancer and melanoma. Evidence of an hypothesized link is an interesting turn of phrase, but the drug's new found potential to treat skin cancer is clearly exciting investors.

Since announcing the "breakthrough" news the stock has tripled in value from 8 cents on Monday to 24 cents today. This is good news for the company as key to the hopes of many early-stage biotech businesses is raising sufficient capital to help fund daily operations and expensive clinical research required to prove a drug's efficacy in treating degenerative human health conditions.

Publically-funded research and development grants or tax benefits granted by the ATO are another important source of funds for early-stage biotech businesses.

Investors should be aware that for every blockbuster success such as liver cancer treatment business Sirtex Medical Limited (ASX: SRX), there are many more businesses that don't succeed. Indeed, Novogen has a significant prior history of announcing capital raisings, breakthrough developments, and important discoveries that have amounted to little so far.

Of course this doesn't stop speculative investors chasing huge returns in the belief that they really have found the next multi-billion dollar global pharmaceutical business.

These kinds of speculative biotech stocks also attract day traders interested in promoting a stock for short-term profits, excited media reports, and public relations spin that may sway some investors into making rash decisions.

It's for these reasons that interested investors should approach this stock with caution and be aware of the considerable risks.

Motley Fool contributor Tom Richardson owns shares in Sirtex Medical Limited. You can find him on Twitter @tommyr345

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »